{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-179817","form_type":"8-K","ticker":"CDXS","cik":"0001200375","company_name":"CODEXIS, INC.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.507218+00:00","generated_at":"2026-05-17T13:52:33.135480+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Codexis Q2 revenue $15.3M beats consensus; net loss narrows to $13.3M from $22.8M YoY","bullets":["Revenue $15.3M, beating $14.1M analyst consensus; net loss $13.3M ($0.16/sh) vs $22.8M ($0.32/sh) YoY.","Product gross margin improved to 72% from 45% YoY on shift to more profitable products.","Raised $27.3M via ATM and Innovatus loan; cash and investments balance $66.3M at Q2 end.","ECO Synthesis platform: over 30 opportunities, 6 presentations at TIDES USA, 3 CDMO collaborations.","Appointed Cynthia Collins (CEO of Nutcracker Therapeutics) to Board of Directors in April 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-179817","json":"https://secwatch.observer/filing/0001193125-25-179817.json","markdown":"https://secwatch.observer/filing/0001193125-25-179817.md","text":"https://secwatch.observer/filing/0001193125-25-179817.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1200375/000119312525179817/0001193125-25-179817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1200375/000119312525179817/d940510d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:52:33.135480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}